

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results  
of a 1-year nationwide programme of the French Cooperative Oncology Group (COCO)

Lancet, The

387, 1415-1426

DOI: [10.1016/s0140-6736\(16\)00004-0](https://doi.org/10.1016/s0140-6736(16)00004-0)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Indications de r�animation en oncologie thoracique. Revue Des Maladies Respiratoires Actualites, 2015, 7, 545-553.	0.0	1
2	Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives. Lung Cancer: Targets and Therapy, 2016, 7, 83.	1.3	6
3	Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedalscience, 2016, 10, 648.	0.6	29
4	Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Translational Lung Cancer Research, 2016, 5, 727-730.	1.3	14
5	Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. PLoS Medicine, 2016, 13, e1002199.	3.9	76
7	Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases. European Respiratory Journal, 2016, 48, 1462-1470.	3.1	32
8	Pharmacogenomics in the age of personalized medicine. Drug Discovery Today: Technologies, 2016, 21-22, 11-16.	4.0	37
9	Cancers des non-fumeurs. Revue Des Maladies Respiratoires Actualites, 2016, 8, 411-416.	0.0	0
10	Les cancers bronchiques non � petites cellules de stade IV Hors addiction oncog�nique : 1 re ligne et maintenance. Revue Des Maladies Respiratoires Actualites, 2016, 8, 351-360.	0.0	2
13	Indications de r�animation en oncologie thoracique. Revue Des Maladies Respiratoires Actualites, 2016, 8, 506-514.	0.0	0
14	Les cancers bronchiques non � petites cellules EGFR-mut�s. Revue Des Maladies Respiratoires Actualites, 2016, 8, 373-381.	0.0	1
15	EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Lung Cancer, 2016, 96, 74-77.	0.9	15
17	Routine molecular profiling of patients with NSCLC � Authors' reply. Lancet, The, 2016, 388, 1054-1055.	6.3	1
18	Routine molecular profiling of patients with NSCLC. Lancet, The, 2016, 388, 1054.	6.3	2
19	Resisting Resistance: Targeted Therapies in Lung Cancer. Trends in Cancer, 2016, 2, 350-364.	3.8	162
21	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opinion on Pharmacotherapy, 2016, 17, 2253-2266.	0.9	26
22	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. Lancet, The, 2016, 388, 1002-1011.	6.3	132
23	New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet, The, 2016, 388, 1012-1024.	6.3	381

#	ARTICLE	IF	CITATIONS
24	Somatic alterations in lung cancer: Do environmental factors matter?. Lung Cancer, 2016, 100, 45-52.	0.9	23
25	Stratified Treatment in Lung Cancer. Oncology Research and Treatment, 2016, 39, 760-766.	0.8	13
26	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. British Journal of Cancer, 2016, 115, 1504-1512.	2.9	55
27	Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. ESMO Open, 2016, 1, e000081.	2.0	6
28	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer, 2016, 102, 122-134.	0.9	180
29	Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. Therapeutic Advances in Respiratory Disease, 2016, 10, 549-565.	1.0	58
30	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v1-v27.	0.6	1,351
31	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncology, The, 2016, 17, 984-993.	5.1	689
32	Making sense of big data in health research: Towards an EU action plan. Genome Medicine, 2016, 8, 71.	3.6	190
33	Alectinib for ALK-positive non-small-cell lung cancer. Expert Review of Clinical Pharmacology, 2016, 9, 1005-1013.	1.3	17
34	Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Molecular Diagnosis and Therapy, 2016, 20, 401-406.	1.6	30
35	Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study. Lung Cancer, 2016, 98, 9-14.	0.9	25
37	The 5000% case: a glimpse into the financial issue of lung cancer treatment. European Respiratory Journal, 2016, 47, 1331-1333.	3.1	2
38	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. Clinical Lung Cancer, 2016, 17, 391-397.	1.1	75
39	First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. Journal of Hematology and Oncology, 2016, 9, 23.	6.9	23
40	Combined BRAF and MEK inhibition in BRAF-mutant NSCLC. Lancet Oncology, The, 2016, 17, 860-862.	5.1	5
41	Large-scale screening for somatic mutations in lung cancer. Lancet, The, 2016, 387, 1354-1356.	6.3	111
43	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung Cancer, 2017, 107, 22-35.	0.9	30

#	ARTICLE	IF	CITATIONS
44	BRAF V600E Mutation Is not Always Present as Expected! A Case Report of Lung and Thyroid Carcinomas. <i>Journal of Thoracic Oncology</i> , 2017, 12, 897-899.	0.5	0
45	Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. <i>Cancer Treatment Reviews</i> , 2017, 53, 128-137.	3.4	146
46	Developments in pharmacotherapy for treating metastatic non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 151-163.	0.9	10
47	Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management. <i>Journal of Controlled Release</i> , 2017, 249, 42-52.	4.8	10
48	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1286437.	2.1	28
50	Optimal management of ALK -positive NSCLC progressing on crizotinib. <i>Lung Cancer</i> , 2017, 106, 58-66.	0.9	33
51	HER2 Transmembrane Domain Mutations: Rare New Target for Non-Small Cell Lung Cancer Therapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, 422-424.	0.5	7
52	Evaluation of a fast and fully automated platform to diagnose EGFR and KRAS mutations in formalin-fixed and paraffin-embedded non-small cell lung cancer samples in less than one day. <i>Journal of Clinical Pathology</i> , 2017, 70, 544-549.	1.0	34
53	Cancer genomics guide clinical practice in personalized medicine. <i>Therapie</i> , 2017, 72, 439-451.	0.6	12
54	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. <i>Journal of Thoracic Oncology</i> , 2017, 12, 963-973.	0.5	56
55	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	5.2	172
56	Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing. <i>International Journal of Oncology</i> , 2017, 50, 1579-1589.	1.4	16
57	EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. <i>Pathology Research and Practice</i> , 2017, 213, 793-798.	1.0	18
58	Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. <i>BMC Public Health</i> , 2017, 17, 324.	1.2	8
59	Treatment of KRAS-Mutant Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1835.	3.8	12
60	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1844.	3.8	281
61	Coexistence of EGFR, KRAS, BRAF, and PIK3CA Mutations and ALK Rearrangement in a Comprehensive Cohort of 326 Consecutive Spanish Nonsquamous NSCLC Patients. <i>Clinical Lung Cancer</i> , 2017, 18, e395-e402.	1.1	30
62	Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 683-694.	1.4	6

#	ARTICLE	IF	CITATIONS
63	Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, 680-688.	0.6	19
64	Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study. <i>Lung Cancer</i> , 2017, 111, 30-37.	0.9	27
65	Lung Adenocarcinoma Survival in EGFR-Mutated African-Caribbean Patients: A Multicenter Study in the French West Indies. <i>Targeted Oncology</i> , 2017, 12, 689-693.	1.7	6
66	Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. <i>Oncologist</i> , 2017, 22, 786-796.	1.9	95
67	A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. <i>Annals of Oncology</i> , 2017, 28, 1523-1531.	0.6	80
68	Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. <i>European Journal of Cancer Care</i> , 2017, 26, e12721.	0.7	16
69	New insights into the role of EMT in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
70	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	7.7	490
71	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	2.3	65
72	Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 63-89.	0.9	10
73	Molecular biomarkers for lung adenocarcinoma. <i>European Respiratory Journal</i> , 2017, 49, 1601734.	3.1	110
74	The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive Plasma T790M in EGFR -mutant NSCLC Patients. <i>EORTC 1613. Clinical Lung Cancer</i> , 2017, 18, 583-588.	1.1	84
75	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 446-457.	0.5	75
76	Drug-sensitive FGFR3 mutations in lung adenocarcinoma. <i>Annals of Oncology</i> , 2017, 28, 597-603.	0.6	36
77	Clinical Outcome of ALK -Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , 2017, 12, 681-688.	0.5	58
78	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. <i>Clinical Lung Cancer</i> , 2017, 18, 303-309.	1.1	13
79	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 1-12.	2.0	67
80	Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. <i>Oncology Letters</i> , 2017, 14, 5611-5618.	0.8	7

#	ARTICLE	IF	CITATIONS
82	Association between lung cancer somatic mutations and occupational exposure in never-smokers. <i>European Respiratory Journal</i> , 2017, 50, 1700716.	3.1	16
83	PD-L1 IHC in NSCLC with a global and methodological perspective. <i>Lung Cancer</i> , 2017, 113, 102-105.	0.9	34
84	A reliable and stable method for determination of brigatinib in rat plasma by UPLC-MS/MS: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 84-89.	1.2	8
86	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1055-1069.	1.5	24
87	Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients. <i>Cancer Science</i> , 2017, 108, 2487-2494.	1.7	57
88	Lung Cancer in the Older Patient. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 563-577.	1.0	20
89	Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. <i>Cancer Treatment Reviews</i> , 2017, 60, 1-11.	3.4	29
90	Functional precision cancer medicine—moving beyond pure genomics. <i>Nature Medicine</i> , 2017, 23, 1028-1035.	15.2	252
91	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1307-1316.	5.1	889
92	Treating <i>KRAS</i> -mutant NSCLC: latest evidence and clinical consequences. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 589-597.	1.4	33
94	Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. <i>Oncology Research and Treatment</i> , 2017, 40, 435-439.	0.8	7
95	The Current Role of Whole Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1467-1477.	0.5	18
96	<i>HER2</i> mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2017, 123, 4099-4105.	2.0	132
97	MEDI 4736 (durvalumab) in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1317-1323.	1.4	14
98	Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study). <i>Targeted Oncology</i> , 2017, 12, 833-838.	1.7	8
99	Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2017, 112, 10-15.	0.9	3
100	LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. <i>Lung Cancer</i> , 2017, 112, 62-68.	0.9	92
101	EGFR tyrosine kinase inhibitors versus chemotherapy in <i>EGFR</i> -wild-type pre-treated advanced nonsmall cell lung cancer in daily practice. <i>European Respiratory Journal</i> , 2017, 50, 1700514.	3.1	20

#	ARTICLE	IF	CITATIONS
102	Current Landscape of Targeted Therapy in Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 757-764.	2.3	134
104	EGFR , KRAS , BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. <i>Experimental and Molecular Pathology</i> , 2017, 103, 306-310.	0.9	21
105	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066.	3.0	37
108	EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. <i>Targeted Oncology</i> , 2017, 12, 663-675.	1.7	12
110	Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. <i>Respiratory Research</i> , 2017, 18, 120.	1.4	41
111	Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database. <i>Clinical and Translational Oncology</i> , 2017, 19, 1537-1542.	1.2	4
112	Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens. <i>European Respiratory Review</i> , 2017, 26, 170007.	3.0	74
113	Systemic and Tumor Th1 and Th2 Inflammatory Profile and Macrophages in Lung Cancer: Influence of Underlying Chronic Respiratory Disease. <i>Journal of Thoracic Oncology</i> , 2017, 12, 235-248.	0.5	33
114	Alectinib for treatment of <i>ALK</i>-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2017, 13, 321-335.	1.1	12
117	A consensus statement on the gender perspective in lung cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 527-535.	1.2	26
118	Les cancers bronchiques non Å petites cellules EGFR-mutÃ©s. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 213-223.	0.0	0
119	Molecular Testing in Lung Cancer. , 2017, , 287-303.		2
121	Prise en charge des patients de stade avancÃ© avec remaniement ALK : aujourdâ€™hui et demain (Ã© qui sera) Tj ETQq0 0 0 ggBT /Over	0.0	0
123	Les nouveaux parcours en oncologie thoracique en 2017. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 360-366.	0.0	0
124	AltÃ©rations molÃ©culaires anciennes et Ã©mergentes : quand les rechercher ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 202-212.	0.0	1
125	EANOâ€™ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. <i>Annals of Oncology</i> , 2017, 28, iv84-iv99.	0.6	331
126	Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. <i>Annals of Oncology</i> , 2017, 28, 2715-2724.	0.6	72
128	Prognostic value of <i>EGFR</i> and <i>KRAS</i> in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 33922-33932.	0.8	40

#	ARTICLE	IF	CITATIONS
130	2016, une année pas tout à fait comme les autres. Revue Des Maladies Respiratoires Actualites, 2017, 9, S1-S3.	0.0	1
131	Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget, 2017, 8, 103055-103062.	0.8	47
132	Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors. Oncotarget, 2017, 8, 105103-105114.	0.8	27
133	Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics. Cancers, 2017, 9, 88.	1.7	5
134	ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients. Cancers, 2017, 9, 106.	1.7	22
135	ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice. Cancers, 2017, 9, 107.	1.7	47
136	Diagnostics for Targeted NSCLC Therapy. Challenges, 2017, 8, 29.	0.9	0
137	Circulating Cell Free Tumor DNA Detection as a Routine Tool for Lung Cancer Patient Management. International Journal of Molecular Sciences, 2017, 18, 264.	1.8	76
138	Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Frontiers in Medicine, 2016, 3, 76.	1.2	74
139	Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 222.	1.3	5
140	Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report. OncoTargets and Therapy, 2017, Volume 10, 4347-4354.	1.0	3
141	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget, 2017, 8, 34796-34810.	0.8	45
142	Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer. PLoS ONE, 2017, 12, e0183319.	1.1	26
143	Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis. BMC Medicine, 2017, 15, 193.	2.3	33
144	Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget, 2017, 8, 21903-21917.	0.8	140
145	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. Oncotarget, 2017, 8, 109818-109835.	0.8	5
146	Targeted therapy for leptomeningeal metastases in non-small cell lung cancer – Changing treatment paradigms. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 535-542.	0.7	10
147	Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 12-17.	1.8	3

#	ARTICLE	IF	CITATIONS
148	Managing Resistance to EGFR- and ALK-Targeted Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 607-618.	1.8	16
149	<i>MET</i> exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. <i>Oncotarget</i> , 2017, 8, 42428-42437.	0.8	47
150	Possible application of circulating free tumor DNA in non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, S1364-S1372.	0.6	13
151	Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?. <i>Translational Lung Cancer Research</i> , 2017, 6, 444-453.	1.3	12
152	Blood-based tumor biomarkers in lung cancer for detection and treatment. <i>Translational Lung Cancer Research</i> , 2017, 6, 648-660.	1.3	51
153	Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. <i>Annals of Oncology</i> , 2018, 29, i28-i37.	0.6	95
154	Correlation analysis of mesenchymal-epithelial transition factor protein and human epidermal growth receptor-2 protein expression in 1479 cases of lung adenocarcinoma in China. <i>Thoracic Cancer</i> , 2018, 9, 439-444.	0.8	2
155	BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. <i>Drugs</i> , 2018, 78, 549-566.	4.9	95
156	Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 118, 62-68.	0.9	15
157	BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 796-797.	1.2	10
158	The role of high-mobility group protein box 1 in lung cancer. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6354-6365.	1.2	15
159	Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. <i>Lung Cancer</i> , 2018, 120, 70-74.	0.9	5
160	Clinical and Pathological Characteristics of <i>KEAP1</i> - and <i>NFE2L2</i> -Mutated Non-Small Cell Lung Carcinoma (NSCLC). <i>Clinical Cancer Research</i> , 2018, 24, 3087-3096.	3.2	116
161	FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> Mutations. <i>Oncologist</i> , 2018, 23, 740-745.	1.9	168
162	Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i> <sup>+</sup> advanced non-small cell lung cancer patients. <i>ERJ Open Research</i> , 2018, 4, 00058-2017.	1.1	8
163	Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 721-726.	0.5	11
164	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 149-161.	2.0	50
165	Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) – Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy. <i>Pathology and Oncology Research</i> , 2018, 24, 723-731.	0.9	21

#	ARTICLE	IF	CITATIONS
166	Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 568-575.	0.5	17
167	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 301-322.	0.5	43
168	ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 116, 15-24.	0.9	44
169	Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma. <i>Laboratory Investigation</i> , 2018, 98, 371-379.	1.7	18
170	Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1049-1055.	0.6	114
171	Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 581-588.	1.4	5
172	Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 3-16.	1.9	81
173	Detection of EGFR, KRAS and BRAF mutations in metastatic cells from cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 748-753.	1.4	6
174	Comprehensive Genomic Profiling of Malignant Effusions in Patients with Metastatic Lung Adenocarcinoma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 184-194.	1.2	35
175	Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients. <i>BMC Bioinformatics</i> , 2018, 19, 40.	1.2	14
176	Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers. <i>BMC Cancer</i> , 2018, 18, 326.	1.1	42
178	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. <i>Cancer Treatment Reviews</i> , 2018, 66, 82-94.	3.4	112
179	Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors versus single agent chemotherapy as second-line treatment for non-small-cell lung cancer wild-type or unknown status for EGFR. <i>The Cochrane Library</i> , 2018, , .	1.5	1
180	Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875961.	1.5	17
181	Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. <i>European Respiratory Journal</i> , 2018, 51, 1701467.	3.1	16
182	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. <i>Clinical Lung Cancer</i> , 2018, 19, 331-339.	1.1	15
183	Genomic Testing in Lung Cancer: Past, Present, and Future. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 323-334.	2.3	20
184	Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. <i>Journal of Medical Economics</i> , 2018, 21, 649-655.	1.0	18

#	ARTICLE	IF	CITATIONS
185	Screening for gene mutations in central nervous system metastases of non-small cell lung cancer. <i>Brain Pathology</i> , 2018, 28, 295-297.	2.1	4
186	Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study. <i>Clinical Lung Cancer</i> , 2018, 19, 93-104.	1.1	41
187	Assessment of BRAFV600E mutation in pulmonary Langerhans cell histiocytosis in tissue biopsies and bronchoalveolar lavages by droplet digital polymerase chain reaction. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 247-258.	1.4	10
188	Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 253-266.	1.5	11
189	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. <i>Modern Pathology</i> , 2018, 31, 307-312.	2.9	24
190	Molecular Testing in Lung Cancer. , 2018, , 164-177.e5.		0
191	Molecular Diagnosis and Targeting for Lung Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 1-32.	0.1	0
193	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutationsâ€”The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	3.2	154
194	Emerging role of extracellular vesicles as a senescence-associated secretory phenotype: Insights into the pathophysiology of lung diseases. <i>Molecular Aspects of Medicine</i> , 2018, 60, 92-103.	2.7	126
195	Mutational Landscape of DDR2 Gene in Lung Squamous Cell Carcinoma Using Next-generation Sequencing. <i>Clinical Lung Cancer</i> , 2018, 19, 163-169.e4.	1.1	11
196	Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 726-739.	1.8	13
197	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	17
198	Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4061-S4064.	0.6	2
199	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018, 10, 3909-3921.	0.6	35
200	Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. <i>Journal of Thoracic Disease</i> , 2018, 10, 2070-2078.	0.6	18
201	Endobronchial ultrasound-guided fine-needle aspiration for pulmonary carcinomas genotyping: experience with 398 cases including rapid EGFR/KRAS analysis in 43 cases. <i>Journal of Thoracic Disease</i> , 2018, 10, 4653-4658.	0.6	7
202	The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 639-646.	1.3	98
203	Circulating Cell-Free Tumor DNA in the Management of Double Primary Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	1

#	ARTICLE	IF	CITATIONS
206	Patients with Non-Small-Cell Lung Cancer Harboring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14. <i>Current Oncology</i> , 2018, 25, 398-402.	0.9	9
207	Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1873-1883.	0.5	30
208	Precision oncology: separating the wheat from the chaff. <i>ESMO Open</i> , 2018, 3, e000446.	2.0	37
210	Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance. <i>Oncotarget</i> , 2018, 9, 15418-15434.	0.8	21
211	Classification histomolaiculaire des cancers pulmonaires. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 236-247.	0.0	0
212	Les addictions oncogéniques : du diagnostic au suivi. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 358-368.	0.0	0
214	Les populations particulières : les personnes âgées atteintes d'un cancer bronchique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 408-415.	0.0	0
215	Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l'EGFR. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 425-439.	0.0	1
216	CBNPC et autres cibles thérapeutiques (BRAF, HER2, MET, RET, NTRK...). <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 446-453.	0.0	0
217	ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 147-155.	0.4	15
218	Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2835.	1.8	74
219	Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France. <i>Oncology</i> , 2018, 95, 337-343.	0.9	16
220	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv192-iv237.	0.6	1,571
221	Increased risk of recurrence in resected EGFR-positive pNOMO invasive lung adenocarcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1594-1602.	0.8	19
222	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. <i>Advances in Anatomic Pathology</i> , 2018, 25, 374-386.	2.4	15
224	PCR-based detection of EGFR, ALK, KRAS and BRAF mutations in Russian patients with lung adenocarcinoma: a single-center experience. <i>Neoplasma</i> , 2018, 65, 972-979.	0.7	8
225	Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. <i>BMC Cancer</i> , 2018, 18, 1013.	1.1	6
227	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	3.4	37

#	ARTICLE	IF	CITATIONS
228	Biologie moléculaire des carcinomes bronchiques : standards actuels et perspectives. Revue Francophone Des Laboratoires, 2018, 2018, 46-51.	0.0	1
229	Updates in Lung Cancer Cytopathology. Surgical Pathology Clinics, 2018, 11, 515-522.	0.7	4
231	MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer, 2018, 125, 57-67.	0.9	25
232	Dabrafenib and trametinib for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1063-1068.	1.1	17
233	Preventing central nervous system metastases in non-small cell lung cancer. Expert Review of Anticancer Therapy, 2018, 18, 1077-1083.	1.1	3
234	Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis. Molecular Cancer Therapeutics, 2018, 17, 2427-2438.	1.9	12
235	Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Annals of Oncology, 2018, 29, 2068-2075.	0.6	132
236	Can Early Clinical Trials Help Deliver More Precise Cancer Care?. , 2018, , 115-128.		0
237	Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer. Lung Cancer, 2018, 121, 76-81.	0.9	38
238	The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer, 2018, 123, 70-75.	0.9	125
239	Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times. European Respiratory Journal, 2018, 51, 1800844.	3.1	1
240	Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times. European Respiratory Journal, 2018, 51, 1800602.	3.1	0
241	Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. Advances in Therapy, 2018, 35, 1035-1048.	1.3	5
242	Association between hospital volume and mortality of patients with metastatic non-small cell lung cancer. Lung Cancer, 2018, 122, 214-219.	0.9	22
243	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. Annals of Internal Medicine, 2018, 169, 233.	2.0	20
244	Clinicopathologic characteristics and survival outcome in patients with advanced lung adenocarcinoma and KRAS mutation. Journal of Cancer, 2018, 9, 2930-2937.	1.2	17
245	CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. Cancers, 2018, 10, 252.	1.7	20
246	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. Expert Opinion on Biological Therapy, 2018, 18, 937-945.	1.4	13

#	ARTICLE	IF	CITATIONS
247	Hardâ€•Drug Repurposing for Precision Oncology: The Missing Link?. <i>Frontiers in Pharmacology</i> , 2018, 9, 637.	1.6	22
248	Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. <i>PLoS ONE</i> , 2018, 13, e0200633.	1.1	31
249	Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. <i>Acta Dermato-Venereologica</i> , 2018, 98, 44-49.	0.6	20
250	Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas. <i>Lung Cancer</i> , 2018, 124, 110-116.	0.9	43
251	Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 88.	1.3	57
252	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018, 7, 144.	1.0	54
253	Lamins in Lung Cancer: Biomarkers and Key Factors for Disease Progression through miR-9 Regulation?. <i>Cells</i> , 2018, 7, 78.	1.8	12
254	Correlation between progressionâ€•free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advancedâ€•stage <i>EGFR</i>-mutated nonâ€•small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1104-1110.	0.8	52
255	Synchronous multiple non-small cell lung cancers in an allograft lung recipient. <i>Lung Cancer</i> , 2018, 124, 291-292.	0.9	3
256	Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma. <i>Open Medicine (Poland)</i> , 2018, 13, 278-280.	0.6	2
257	Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?. <i>Cancers</i> , 2018, 10, 70.	1.7	21
258	A systematic review of targeted agents for non-small cell lung cancer. <i>Acta OncolÃ³gica</i> , 2018, 57, 176-186.	0.8	54
260	Comparison of detection methods of &lt;em>EGFR</em> T790M mutations using plasma, serum, and tumor tissue in EGFR-TKI-resistant non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3335-3343.	1.0	20
261	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Tj ETQq1 1 0.784314 rgBT /Overlock		
262	Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 863-873.	5.2	224
263	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 694-708.	12.5	255
264	Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Nonâ€•Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, e215-e217.	0.5	12
265	Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. <i>Lung Cancer</i> , 2018, 122, 72-75.	0.9	46

#	ARTICLE	IF	CITATIONS
266	KRAS: Reasons for optimism in lung cancer. <i>European Journal of Cancer</i> , 2018, 99, 20-27.	1.3	43
267	Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). <i>Lung Cancer</i> , 2019, 136, 109-114.	0.9	16
268	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1448.	3.4	94
269	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing. <i>Cancer</i> , 2019, 125, 4043-4051.	2.0	14
270	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 121-133.	1.1	4
271	Effect and biomarker of Nivolumab for non-small-cell lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109199.	2.5	22
272	Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patients. <i>Future Oncology</i> , 2019, 15, 2139-2149.	1.1	2
273	Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. <i>BMC Cancer</i> , 2019, 19, 701.	1.1	10
274	Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. <i>Journal of Thoracic Disease</i> , 2019, 11, 2383-2391.	0.6	3
275	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. <i>Frontiers in Immunology</i> , 2019, 10, 1505.	2.2	34
276	Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. <i>Clinical Drug Investigation</i> , 2019, 39, 1003-1007.	1.1	6
277	Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies. <i>RSC Advances</i> , 2019, 9, 17921-17932.	1.7	2
278	Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation. <i>Journal of Thoracic Oncology</i> , 2019, 14, e151-e153.	0.5	3
279	KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 951-954.	0.5	4
280	Clonality analysis of pulmonary tumors by genome-wide copy number profiling. <i>PLoS ONE</i> , 2019, 14, e0223827.	1.1	9
281	Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. <i>BMJ: British Medical Journal</i> , 2019, 367, l5460.	2.4	108
282	Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study. <i>Lung Cancer</i> , 2019, 137, 149-156.	0.9	63
283	Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 531-541.	1.0	8

#	ARTICLE	IF	CITATIONS
284	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. The Cochrane Library, 2019, , .	1.5	3
285	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. <i>Frontiers in Medicine</i> , 2019, 6, 233.	1.2	8
286	Frequency and outcomes of brain metastases in patients with <i>HER2</i> -mutant lung cancers. <i>Cancer</i> , 2019, 125, 4380-4387.	2.0	51
287	Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	8
288	ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma. <i>Diagnostic Pathology</i> , 2019, 14, 96.	0.9	11
289	The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. <i>Journal of Translational Medicine</i> , 2019, 17, 298.	1.8	33
290	Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments. <i>Cancers</i> , 2019, 11, 1374.	1.7	61
291	Effect of gefitinib on serum EGFR and CYFRA211 in patients with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 18, 4167-4175.	0.8	2
292	The potential use of big data in oncology. <i>Oral Oncology</i> , 2019, 98, 8-12.	0.8	40
293	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	1.3	95
294	Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS@ phase II trial. <i>Annals of Oncology</i> , 2019, 30, 1985-1991.	0.6	128
295	Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2). <i>Clinical Lung Cancer</i> , 2019, 20, 222-230.	1.1	3
296	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	1.3	69
297	Detection of Circulating Tumor DNA with a Single-Molecule Sequencing Analysis Validated for Targeted and Immunotherapy Selection. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 521-535.	1.6	10
298	Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019, 4, e000498.	2.0	38
300	When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2019, 20, 60.	1.3	30
301	A Rare Fusion of CLIP1 and ALK in a Case of Non-Small-Cell Lung Cancer With Neuroendocrine Features. <i>Clinical Lung Cancer</i> , 2019, 20, e535-e540.	1.1	4
302	Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. <i>European Journal of Cancer</i> , 2019, 116, 86-97.	1.3	18

#	ARTICLE	IF	CITATIONS
303	Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1897-1905.	1.2	4
304	Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02â€“14. <i>Advances in Therapy</i> , 2019, 36, 2161-2166.	1.3	11
305	Cas clinique nÂ° 5 : Adaptation thÃ©rapeutique chez un patient atteint de cancer du poumon EGFR-mutÃ©. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 34-37.	0.0	0
306	SYNTHÃˆSE NÂ° 2. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 47-54.	0.0	0
307	Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. <i>Lung Cancer</i> , 2019, 134, 225-232.	0.9	10
308	Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2019, 14, 307-314.	1.7	7
309	Simultaneous inhibition of PI3KÎ± and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 66.	1.4	21
310	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	0.5	99
311	Itâ€™s far better to be alone than to be in bad company. <i>Journal of Thoracic Disease</i> , 2019, 11, 649-651.	0.6	1
312	Computed Tomography Imaging Characteristics of Nonâ€“Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 339-349.	1.1	24
313	Comparison of cobas<i>EGFR</i> Mutation Test v2 and PANAMutyper-R-<i>EGFR</i> for Detection and Semi-Quantification of Epidermal Growth Factor Receptor Mutations in Plasma and Pleural Effusion Supernatant. <i>Annals of Laboratory Medicine</i> , 2019, 39, 478-487.	1.2	11
314	Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 165.	3.5	15
315	Real-World Utility of an Amplicon-Based Next-Generation Sequencing Liquid Biopsy for Broad Molecular Profiling in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	31
316	New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. <i>General Hospital Psychiatry</i> , 2019, 60, 148-155.	1.2	24
317	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1095-1101.	0.5	159
318	Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982707.	0.8	13
319	Pneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790â€“M point mutation: a case report. <i>BMC Cancer</i> , 2019, 19, 186.	1.1	8
320	Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Nonâ€“Small Cell Lung Cancer Using a Clinicogenomic Database. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1391.	3.8	370

#	ARTICLE	IF	CITATIONS
321	Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1137-1148.	1.9	0
322	In situ cancer diagnosis through online plasmonics. <i>Biosensors and Bioelectronics</i> , 2019, 131, 104-112.	5.3	68
323	Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661983190.	1.0	34
324	Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, S89-S101.	0.6	52
325	Cyclopamine tartrate, a modulator of hedgehog signaling and mitochondrial respiration, effectively arrests lung tumor growth and progression. <i>Scientific Reports</i> , 2019, 9, 1405.	1.6	20
326	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. <i>Journal of Thoracic Disease</i> , 2019, 11, S113-S126.	0.6	45
327	Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?. <i>Future Oncology</i> , 2019, 15, 1363-1383.	1.1	10
328	Les patients ALK et ROS1: quelle sÃ©quence ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 380-391.	0.0	0
329	Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. <i>Oncologist</i> , 2019, 24, 963-972.	1.9	16
330	OncogÃ©ne pulmonaire: comprendre les addictions oncogÃ©niques et les rÃ©sistances. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 184-192.	0.0	0
331	ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. <i>Lung Cancer</i> , 2019, 138, 13-18.	0.9	8
332	Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 0, , .	1.5	2
333	La rÃ©animation des patients cancÃ©reux Ã  l'heure de l'immunothÃ©rapie et des thÃ©rapies ciblÃ©es. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 418-425.	0.0	0
334	Quel avenir pour les biopsies liquides en oncologie thoracique ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, 436-443.	0.0	0
335	Anaplastic Lymphoma Kinase (ALK)-positive Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 337-344.	0.6	6
337	Old Soldiers Never Die: Is There Still a Role for Immunohistochemistry in the Era of Next-Generation Sequencing Panel Testing?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2035-2038.	0.5	10
338	Treatment of oncogene-driven non-small cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 300-307.	1.2	7
339	Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 667-671.	0.6	4

#	ARTICLE	IF	CITATIONS
340	Prognostic significance of anaplastic lymphoma kinase rearrangement in patients with completely resected lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2019, 11, 4258-4270.	0.6	11
341	Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer. <i>BMC Cancer</i> , 2019, 19, 1237.	1.1	19
342	Tumour Suppressor Genes with Oncogenic Roles in Lung Cancer. , 0, , .		1
343	A review of canakinumab and its therapeutic potential for non-small cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 879-885.	0.7	15
345	Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.	1.5	0
346	Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	81
347	Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 158-165.	3.2	81
348	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. <i>Cancer Letters</i> , 2019, 444, 147-161.	3.2	13
349	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 128, 74-90.	0.9	13
350	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2019, 30, 171-210.	0.6	214
351	Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. <i>Lung Cancer</i> , 2019, 127, 96-102.	0.9	31
352	Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. <i>Investigational New Drugs</i> , 2019, 37, 498-506.	1.2	7
353	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e338-e345.	1.1	14
354	Somatic mutations and immune checkpoint biomarkers. <i>Respirology</i> , 2019, 24, 215-226.	1.3	9
355	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e208-e217.	1.1	9
356	Epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer: what is the preferred first-line therapy?. <i>Current Opinion in Oncology</i> , 2019, 31, 1-7.	1.1	19
357	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2019, 22, 140-150.	1.0	17
358	Molecular Diagnostics in Cytopathology. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
359	Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 11-17.	1.1	6
360	Molecular Diagnostics in Lung Cytology. , 2019, , 223-247.		0
361	A liquid biopsy in primary lung cancer. <i>Surgery Today</i> , 2019, 49, 1-14.	0.7	12
362	TTF-1-positive Metastatic Endometrioid Carcinoma: A Case Report and Review of Literature of a Potential Diagnostic Pitfall. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, e6-e9.	0.6	4
363	Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2020, 22, 823-834.	1.2	29
364	High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 120-124.	0.5	24
365	Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2020, 22, 708-716.	1.2	6
366	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 60-67.	0.9	88
367	Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. <i>Clinical and Translational Oncology</i> , 2020, 22, 294-301.	1.2	4
368	Cryobiopsy increases the EGFR detection rate in non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 141, 56-63.	0.9	20
369	Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: Diagnostic performances for pathological diagnosis and molecular testing. <i>Lung Cancer</i> , 2020, 140, 93-98.	0.9	9
370	U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 20-28.	0.2	15
371	Oncogene addiction and tumor mutational burden in non-small cell lung cancer: Clinical significance and limitations. <i>Thoracic Cancer</i> , 2020, 11, 205-215.	0.8	22
372	Prognostic and therapeutic significance of circulating tumor cells in patients with lung cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 31-49.	2.1	35
373	Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. <i>Lung Cancer</i> , 2020, 140, 19-26.	0.9	16
374	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	0.5	102
375	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	0.9	79
376	Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 66.	1.8	12

#	ARTICLE	IF	CITATIONS
377	Histopathological and molecular study for synchronous lung adenocarcinoma staging. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 835-842.	1.4	16
378	Precision medicine. , 2020, , 389-396.		0
379	Non-small cell lung cancer targetable mutations: present and future. Precision Cancer Medicine, 0, 3, 5-5.	1.8	3
380	Molecular Pathology of Primary Non-small Cell Lung Cancer. Archives of Medical Research, 2020, 51, 784-798.	1.5	55
381	Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer. Translational Lung Cancer Research, 2020, 9, 1599-1605.	1.3	0
382	Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors. Journal of Thoracic Disease, 2020, 12, 4643-4650.	0.6	19
385	Traitement des cancers bronchiques non Ā petites cellules de stades avancĀs mutĀs EGFR : quels inhibiteurs ? Quelles sĀquences thĀrapeutiques ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S195-2S211.	0.0	2
386	Les patients ALK et ROS1 : quelle sĀquence ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S212-2S222.	0.0	0
387	La prise en charge des mĀtastases cĀrĀbrales du cancer bronchique. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S233-2S242.	0.0	0
388	Quel avenir pour les biopsies liquides en oncologie thoracique ?. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S299-2S306.	0.0	0
389	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 1491-1505.	0.6	658
390	A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients. World Journal of Surgical Oncology, 2020, 18, 172.	0.8	6
391	Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC). Journal of Medical Economics, 2020, 23, 1123-1129.	1.0	14
392	First-line immune-chemotherapy combination for squamous NSCLC is already a reality. Translational Lung Cancer Research, 2020, 9, 819-823.	1.3	1
393	Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Pre-amplification before PNA-Mediated PCR Clamping and Pyrosequencing. Diagnostics, 2020, 10, 527.	1.3	5
394	Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases. Annals of Palliative Medicine, 2020, 9, 2062-2071.	0.5	10
395	Spinal metastases from lung cancer: Survival depends only on genotype, neurological and personal status, scarcely of surgical resection. Surgical Oncology, 2020, 34, 51-56.	0.8	15
396	Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer. BMC Cancer, 2020, 20, 699.	1.1	6

#	ARTICLE	IF	CITATIONS
397	Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments. <i>Value in Health</i> , 2020, 23, 898-906.	0.1	7
399	Stemness Related Genes Revealed by Network Analysis Associated With Tumor Immune Microenvironment and the Clinical Outcome in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 549213.	1.1	47
400	Impact of Somatic Mutations in Non-Small-Cell Lung Cancer: A Retrospective Study of a Chinese Cohort. <i>Cancer Management and Research</i> , 2020, Volume 12, 7427-7437.	0.9	2
401	Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. <i>Cancer Cytopathology</i> , 2020, 128, 601-610.	1.4	13
402	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with BRAF-Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6242-6253.	3.2	23
403	A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies. <i>Cancer Management and Research</i> , 2020, Volume 12, 6493-6509.	0.9	19
404	Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 602762.	1.3	59
405	Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities. <i>Diagnostics</i> , 2020, 10, 1092.	1.3	13
406	Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIRO2-Lung Trial. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100068.	0.6	10
407	Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. <i>Cancer Management and Research</i> , 2020, Volume 12, 12593-12602.	0.9	11
408	Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. <i>Cancers</i> , 2020, 12, 3608.	1.7	8
409	Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2020, 8, 730.	2.1	6
410	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	1.3	1
411	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
412	Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101071.	0.2	2
413	Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 109996.	2.5	35
414	Bioinformatics Analysis Reveals Biomarkers With Cancer Stem Cell Characteristics in Lung Squamous Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 427.	1.1	62
415	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65

#	ARTICLE	IF	CITATIONS
416	Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2020, 11, 1869-1875.	0.8	1
417	Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer. <i>Cancer Medicine</i> , 2020, 9, 4501-4511.	1.3	8
418	Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 211-223.	1.3	53
419	Integrating Genetic and Genomic Testing Into Oncology Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e259-e263.	1.8	6
420	Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. <i>Journal of the American Society of Cytopathology</i> , 2020, 9, 332-345.	0.2	21
421	Pharmacological and clinical properties of lorlatinib in the treatment of <i>ALK</i> -rearranged advanced non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1547-1554.	0.9	13
422	Primary CNS Metastatic BRAF-mutated Lung Adenocarcinoma With Complete Intracranial Response to BRAF/MEK Inhibition. <i>Clinical Lung Cancer</i> , 2020, 21, e544-e546.	1.1	3
423	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. <i>Diagnostics</i> , 2020, 10, 359.	1.3	51
424	Improvement strategies for successful next-generation sequencing analysis of lung cancer. <i>Future Oncology</i> , 2020, 16, 1597-1608.	1.1	14
425	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 386-399.	0.8	3
426	Healthcare and Artificial Intelligence. , 2020, , .		15
427	Risk factors of acquired T790M mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. <i>Journal of Cancer</i> , 2020, 11, 2060-2067.	1.2	7
428	Forced degradation of Ceritinib under stress conditions: Structural interpretation of novel degradants using HR-MS/MS and NMR. <i>Materials Today: Proceedings</i> , 2020, 33, 2067-2076.	0.9	1
429	Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100052.	0.6	9
430	Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study. <i>PLoS ONE</i> , 2020, 15, e0234387.	1.1	3
431	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. <i>Cancer Treatment Reviews</i> , 2020, 89, 102067.	3.4	48
432	&lt;p&gt;Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 4029-4038.	0.9	7
433	Molecular therapeutic targets in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 647-661.	1.1	46

#	ARTICLE	IF	CITATIONS
434	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	0.5	29
435	Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer. <i>European Journal of Health Economics</i> , 2020, 21, 881-893.	1.4	1
437	Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis. <i>Thoracic Cancer</i> , 2020, 11, 851-866.	0.8	22
438	Evolving use of liquid biopsy in non-small-cell-lung cancer patients. <i>International Journal of Biological Markers</i> , 2020, 35, 23-25.	0.7	3
439	The Biology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 25-38.	0.8	52
440	Next generation sequencing in lung cancer: An initial experience from India. <i>Current Problems in Cancer</i> , 2020, 44, 100562.	1.0	5
441	Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations. <i>Clinical Lung Cancer</i> , 2020, 21, 395-406.	1.1	2
442	Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. <i>Journal of Thoracic Oncology</i> , 2020, 15, 628-636.	0.5	185
443	A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 142, 34-40.	0.9	27
445	Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. <i>PLoS ONE</i> , 2020, 15, e0226196.	1.1	12
446	Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. <i>Annals of Oncology</i> , 2020, 31, 289-294.	0.6	105
447	Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1000-1014.	0.5	68
448	First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. <i>Cancer Medicine</i> , 2020, 9, 2309-2316.	1.3	35
449	<sup>low</sup>/> pHER2<sup>high</sup> signature in non-small cell lung cancer is predictive of anti-HER2 molecule efficacy. <i>Journal of Pathology</i> , 2020, 251, 187-199.	2.1	12
450	Weighted Gene Coexpression Network Analysis of Features That Control Cancer Stem Cells Reveals Prognostic Biomarkers in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 311.	1.1	99
451	Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma. <i>European Radiology</i> , 2020, 30, 5021-5028.	2.3	10
452	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	1.5	36
453	A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1073-1077.	0.5	8

#	ARTICLE	IF	CITATIONS
454	Non-amplification genetic alterations of <i>HER2</i> gene in non-small cell lung carcinoma. <i>Journal of Clinical Pathology</i> , 2021, 74, 106-110.	1.0	5
455	Osimertinib in patients with advanced/metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer - the Belgian ASTRIS data. <i>Acta Clinica Belgica</i> , 2021, 76, 224-231.	0.5	1
456	Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 152, 174-184.	0.9	53
457	Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e54-e56.	1.1	3
458	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 452-463.	0.5	51
459	PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project. <i>Lung Cancer</i> , 2021, 151, 69-75.	0.9	12
460	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 357-363.	0.8	15
461	Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1177-1188.	2.0	60
462	Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). <i>Oncologist</i> , 2021, 26, e435-e444.	1.9	5
463	6-Color Crystal Digital PCRTM for the High-Plex Detection of EGFR Mutations in Non-Small Cell Lung Cancer. <i>Methods in Molecular Biology</i> , 2021, 2279, 127-144.	0.4	4
464	BRAF Mutations and Resistance of Non-Small Cell Lung Cancer to BRAF-Targeted Therapies Using Liquid Biopsy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 110-111.	0.7	3
465	Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1650-1671.	1.7	50
466	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. <i>Oncolmmunology</i> , 2021, 10, 1957603.	2.1	10
468	An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology. <i>Laboratory Investigation</i> , 2021, 101, 648-660.	1.7	6
469	Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 93-102.	1.5	31
470	Estimation of the incidence of molecular disorders in the tumor cells in breast malignant neoplasms by high-throughput sequencing. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 23.	0.0	0
471	Management of Brain Metastases. <i>Current Cancer Research</i> , 2021, , 115-137.	0.2	0
472	Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations. <i>Cells</i> , 2021, 10, 354.	1.8	9

#	ARTICLE	IF	CITATIONS
473	CircMED13L_012 promotes lung adenocarcinoma progression by upregulation of MAPK8 mediated by miR-433-3p. <i>Cancer Cell International</i> , 2021, 21, 111.	1.8	7
474	Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2021, 11, 1672-1687.	7.7	112
475	If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3025.	1.8	5
476	Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China. <i>Frontiers in Oncology</i> , 2021, 11, 630717.	1.3	8
477	Malfeasance of KRAS mutations in carcinogenesis. <i>Clinical and Experimental Medicine</i> , 2021, 21, 439-445.	1.9	1
478	KRAS mutation as a mechanism of resistance to Alectinib in ALK rearranged NSCLC. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100055.	0.1	0
479	Gene Amplification-Associated Overexpression of the Selenoprotein tRNA Enzyme TRIT1 Confers Sensitivity to Arsenic Trioxide in Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1869.	1.7	6
480	KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). <i>Lung Cancer</i> , 2021, 154, 51-61.	0.9	43
481	MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. <i>JCO Precision Oncology</i> , 2021, 5, 653-663.	1.5	50
482	Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers. <i>Scientific Reports</i> , 2021, 11, 10470.	1.6	7
483	Abnormal Expression and Prognostic Significance of Bone Morphogenetic Proteins and Their Receptors in Lung Adenocarcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-23.	0.9	5
484	Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. <i>Cells</i> , 2021, 10, 1206.	1.8	17
486	Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 587-589.	0.6	1
487	ALTA-2: Phase II Study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib. <i>Future Oncology</i> , 2021, 17, 1709-1719.	1.1	10
488	Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. <i>Lung Cancer</i> , 2021, 155, 163-169.	0.9	23
489	BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. <i>European Journal of Cancer</i> , 2021, 149, 211-221.	1.3	9
490	Lenvatinib Induces AKT/NF- $\kappa$ B Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo. <i>Anticancer Research</i> , 2021, 41, 2867-2874.	0.5	2
491	Potential of German claims data to characterize utilization of new cancer drugs: the example of crizotinib. <i>Future Oncology</i> , 2021, 17, 2305-2313.	1.1	1

#	ARTICLE	IF	CITATIONS
492	Metabolic Changes in Early-Stage Non-Small Cell Lung Cancer Patients after Surgical Resection. <i>Cancers</i> , 2021, 13, 3012.	1.7	9
493	Lung cancer in older patients. <i>Innovative Medicine of Kuban</i> , 2021, , 65-71.	0.0	0
494	Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6288.	1.8	51
495	Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2890-2916.	1.3	21
496	What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy. <i>Journal of Molecular Pathology</i> , 2021, 2, 147-172.	0.5	9
497	A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4-years by switching to ceritinib. <i>Thoracic Cancer</i> , 2021, 12, 2225-2228.	0.8	3
498	Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3457-3472.	1.3	1
499	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 157, 9-16.	0.9	7
500	Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer. <i>World Journal of Surgical Oncology</i> , 2021, 19, 197.	0.8	6
501	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). <i>Lung Cancer</i> , 2021, 157, 124-130.	0.9	5
502	Immune Microenvironment Signatures as Biomarkers to Predict Early Recurrence of Stage Ia-b Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 680287.	1.3	18
503	Cyclodextrin-based gefitinib nanobubbles for synergistic apoptosis in lung cancer. <i>Materials Technology</i> , 2022, 37, 1665-1676.	1.5	6
504	Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives. <i>Cancer Letters</i> , 2021, 514, 38-47.	3.2	30
505	First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly. <i>Current Oncology Reports</i> , 2021, 23, 119.	1.8	4
506	Identification of novel ALK fusions using DNA/RNA sequencing in immunohistochemistry / RT-PCR discordant NSCLC patients. <i>Human Pathology</i> , 2021, 114, 90-98.	1.1	5
507	The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. <i>Cancers</i> , 2021, 13, 3923.	1.7	33
508	Complete metabolic response following anaplastic lymphoma kinase (ALK) targeted therapy in a patient with adenocarcinoma of unknown primary with immunohistochemistry/fluorescence in situ hybridisation discordant ALK test results. <i>Internal Medicine Journal</i> , 2021, 51, 1355-1356.	0.5	0
509	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	3

#	ARTICLE	IF	CITATIONS
510	Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). <i>Future Oncology</i> , 2021, 17, 4237-4247.	1.1	11
511	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. <i>Seminars in Cancer Biology</i> , 2022, 84, 293-301.	4.3	30
512	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 987-996.	0.4	1
513	Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
514	Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report. <i>Investigational New Drugs</i> , 2022, 40, 190-193.	1.2	4
515	Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in <i>KRAS</i> mutant cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e13193.	3.3	11
516	Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 76-88.	0.5	37
517	Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals. <i>Chest</i> , 2021, 160, 1121-1130.	0.4	2
518	Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib. <i>Precision Cancer Medicine</i> , 0, 4, 28-28.	1.8	2
519	External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay. <i>Anticancer Research</i> , 2021, 41, 4609-4617.	0.5	5
520	Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 691253.	1.2	0
521	Histopathological and molecular profiling of lung adenocarcinoma skin metastases reveals specific features. <i>Histopathology</i> , 2021, 79, 1051-1060.	1.6	4
522	Targeted therapies for unresectable stage III non-small cell lung cancer. <i>Mediastinum</i> , 2021, 5, 22-22.	0.6	7
523	Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. <i>Pathology and Oncology Research</i> , 2021, 27, 1609963.	0.9	2
524	Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first-line treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1357-1370.	1.3	7
525	Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4671-4692.	1.0	6
526	Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. <i>Molecular Oncology</i> , 2021, 15, 2910-2922.	2.1	23
527	Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Pharmaceutics</i> , 2021, 13, 1478.	2.0	9

#	ARTICLE	IF	CITATIONS
528	Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring. <i>Cancers</i> , 2021, 13, 4926.	1.7	52
529	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	1.8	10
530	A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance. <i>Frontiers in Oncology</i> , 2021, 11, 722039.	1.3	12
531	Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112190.	2.5	24
532	Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras). , 2022, , 889-904.		0
533	CT texture analysis for prediction of EGFR mutational status and ALK rearrangement in patients with non-small cell lung cancer. <i>Radiologia Medica</i> , 2021, 126, 786-794.	4.7	46
534	N <sup>6</sup> -Adenosine Methyltransferase METTL3 is a Positive Prognostic Biomarker in Lung Squamous Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
535	Immune Resistance in Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 384.	1.7	82
536	Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review. <i>Targeted Oncology</i> , 2020, 15, 279-299.	1.7	14
537	The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1434-1448.	0.5	107
538	Personalized therapy for lung cancer: Striking a moving target. <i>JCI Insight</i> , 2018, 3, .	2.3	114
539	Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989575.	1.4	39
540	Rapid Diagnosis of Lung Tumors, a Feasibility Study Using MALDI-ToF Mass Spectrometry. <i>PLoS ONE</i> , 2016, 11, e0155449.	1.1	5
541	In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy. <i>PLoS ONE</i> , 2017, 12, e0180576.	1.1	8
542	Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. <i>Aging</i> , 2020, 12, 7129-7162.	1.4	6
543	Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 8717-8725.	0.8	9
544	Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians. <i>Oncotarget</i> , 2017, 8, 50792-50803.	0.8	2
545	High-throughput detection of clinically targetable alterations using next-generation sequencing. <i>Oncotarget</i> , 2017, 8, 40345-40358.	0.8	14

#	ARTICLE	IF	CITATIONS
546	Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 25189-25199.	0.8	12
547	Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. <i>Oncotarget</i> , 2017, 8, 57379-57385.	0.8	9
548	Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. <i>Oncotarget</i> , 2017, 8, 77897-77914.	0.8	19
549	Evaluation of pre-analytical conditions and comparison of the performance of several digital PCR assays for the detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0 study. <i>Oncotarget</i> , 2017, 8, 87980-87996.	0.8	30
550	EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 98384-98393.	0.8	58
551	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	0.8	12
552	Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. <i>Oncotarget</i> , 2018, 9, 12805-12811.	0.8	2
553	Cross-platform comparison for the detection of RAS mutations in cfDNA (ddPCR Biorad detection) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	46
554	Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. <i>Oncotarget</i> , 2018, 9, 35181-35194.	0.8	30
555	Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. <i>Oncotarget</i> , 2016, 7, 46628-46635.	0.8	36
556	Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 700-713.	1.4	33
557	The KEY to the end of chemotherapy in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2017, 5, 166-166.	0.7	4
558	Osimertinib in first-line treatment is a comparison not proof?. <i>Annals of Translational Medicine</i> , 2018, 6, 57-57.	0.7	3
559	Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report. <i>Annals of Translational Medicine</i> , 2019, 7, 106-106.	0.7	11
560	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 351-351.	0.7	14
561	MicroRNAs in Lung Cancer Oncogenesis and Tumor Suppression: How it Can Improve the Clinical Practice?. <i>Current Genomics</i> , 2020, 21, 372-381.	0.7	1
562	Care of patients with non-small-cell lung cancer stage III the Central European real-world experience. <i>Radiology and Oncology</i> , 2020, 54, 209-220.	0.6	8
563	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	1.7	5

#	ARTICLE	IF	CITATIONS
564	Comprehensive Genomic Profiling for Non-Small-Cell Lung Cancer: Health and Budget Impact. <i>Current Oncology</i> , 2020, 27, 569-577.	0.9	14
565	A nomogram for the prediction of overall survival in patients with stage II and III non-small cell lung cancer using a population-based study. <i>Oncology Letters</i> , 2019, 18, 5905-5916.	0.8	18
566	Emerging non-invasive detection methodologies for lung cancer (Review). <i>Oncology Letters</i> , 2020, 19, 3389-3399.	0.8	7
567	Clinicopathological features and diagnostic methods of ALK fusion-positive non-small cell lung cancer in Korea. <i>Oncology Reports</i> , 2020, 43, 218-228.	1.2	5
569	Les patients ALK et ROS1 : quelle séquence ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2021, 13, 2S174-2S184.	0.0	0
571	Recent advances and new insights in the management of early-stage epidermal growth factor receptor-mutated non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2021, 12, 912-925.	0.9	4
572	Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 1611-1624.	1.5	7
573	H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation. <i>Medical Science Monitor</i> , 2022, 27, e933447.	0.5	1
574	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy. <i>Cancers</i> , 2021, 13, 5132.	1.7	9
575	Heme Sequestration Effectively Suppresses the Development and Progression of Both Lung Adenocarcinoma and Squamous Cell Carcinoma. <i>Molecular Cancer Research</i> , 2022, 20, 139-149.	1.5	5
576	Lung Cancer in Older Adults: Systemic Treatment. , 2018, , 1-13.		0
577	Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 281-285.	0.7	1
578	Enjeux et difficultés de la gestion des médicaments oncothérapeutiques non injectables dans la liste en sus pour un hôpital traitant des cancers. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 1003-1012.	0.0	0
579	Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña : consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO).. <i>Revista Colombiana De Hematología Y Oncología</i> , 2018, 5, 61-71.	0.0	1
580	Klinik Hastalarında Onkogen Mutasyonların Araştırılması, Sileyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 0, .	0.0	0
581	BRAF: Novel Therapies for an Emerging Target. <i>Current Cancer Research</i> , 2019, , 79-100.	0.2	0
582	Les avancées dans la prise en charge des cancers bronchopulmonaires : ce qui change pour le réanimateur. <i>Medecine Intensive Reanimation</i> , 2019, 28, 290-299.	0.1	0
585	Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.. <i>Revista Colombiana De Hematología Y Oncología</i> , 2019, 6, 10-22.	0.0	0

#	ARTICLE	IF	CITATIONS
586	Traitement des cancers bronchiques non À petites cellules de stades avancÃ©s mutÃ©s EGFR: quelle(s) sÃ©quence(s) ?. Revue Des Maladies Respiratoires Actualites, 2019, 11, 364-379.	0.0	0
587	Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anti-Cancer Drugs, 2021, 32, 105-110.	0.7	1
588	Cancers bronchiques. , 2020, , 139-146.e2.		0
589	Integrative public data-mining pipeline for the validation of novel independent prognostic biomarkers for lung adenocarcinoma. Biomarkers in Medicine, 2020, 14, 1651-1662.	0.6	0
590	<p>Survival Analysis of Antineoplastic Treatment for Older Patients with Metastatic Non-Small-Cell Lung Cancer: A Clinical Database Study</p>. Cancer Management and Research, 2020, Volume 12, 12957-12964.	0.9	0
591	Identification of a novel ALK variant intrinsically resistant to crizotinib. Current Problems in Cancer Case Reports, 2020, 2, 100040.	0.1	1
592	Experience of targeted therapy for ALK positive non-small cell lung cancer â€“ a clinical case. Meditsinskiy Sovet, 2020, , 181-186.	0.1	0
593	Tratamiento de cÃ¡ncer de pulmÃ³n metastÃ¡sico (estadio IV) : segundo consenso de expertos, AsociaciÃ³n Colombiana de HematologÃa y OncologÃa (ACHO), 2019.. Revista Colombiana De HematologÃa Y OncologÃa, 2019, 6, 10-22.	0.0	0
594	Lung Cancer in Older Adults: Systemic Treatment. , 2020, , 799-811.		0
596	Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy. Frontiers in Oncology, 2021, 11, 761986.	1.3	2
597	Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer. Cureus, 2020, 12, e9437.	0.2	1
598	CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS. Siberian Journal of Oncology, 2020, 19, 132-137.	0.1	0
599	Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. Respiratory Medicine and Research, 2021, 80, 100795.	0.4	5
600	Two Paradoxes in Linear Regression Analysis. Shanghai Archives of Psychiatry, 2016, 28, 355-360.	0.7	1
601	Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2020, 13, 525-535.	0.5	1
602	Detection of carcinoma in serous effusions: a review. American Journal of Cancer Research, 2021, 11, 43-60.	1.4	2
603	Bronchoalveolar Lavage as a Potential Diagnostic Specimens to Genetic Testing in Advanced Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0
604	Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: results of the IFCT-GFPC-1101 multicenter randomized phase III trial. Lung Cancer, 2021, 164, 84-90.	0.9	0

#	ARTICLE	IF	CITATIONS
605	Survival-associated N6-adenosine methyltransferase signatures in lung squamous cell carcinoma and clinical verification. <i>BMC Cancer</i> , 2021, 21, 1265.	1.1	2
606	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. <i>Cancer Research and Treatment</i> , 2022, 54, 1-9.	1.3	9
607	“Lazarus effect” in patient affected by lung adenocarcinoma carrying EGFR, CTNNB1, MET exon 11 and PIK3CA mutations treated with gefitinib. <i>Precision Cancer Medicine</i> , 0, 3, 23-23.	1.8	1
608	EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature. , 2021, 4, 1019-1027.		1
609	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-“Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 719-728.	0.8	37
610	Targeted therapy for advanced anaplastic lymphoma kinase ( <i>ALK</i> )-rearranged non-small cell lung cancer. <i>The Cochrane Library</i> , 2022, 2022, CD013453.	1.5	18
611	Human Epidermal Growth Factor Receptor 2 “Mutant Non-“Small-Cell Lung Cancer: Continued Progress But Challenges Remain. <i>Journal of Clinical Oncology</i> , 2022, 40, 693-697.	0.8	1
612	Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study. <i>Investigational New Drugs</i> , 2022, 40, 634-642.	1.2	8
613	Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 209-219.	5.1	87
614	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2022, 7, 100333.	2.0	16
615	ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 466-487.	0.6	67
616	Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies. <i>Frontiers in Oncology</i> , 2022, 12, 796832.	1.3	34
617	Pretreatment Thoracic CT Radiomic Features to Predict Brain Metastases in Patients With ALK-Rearranged Non-Small Cell Lung Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 772090.	1.1	3
618	Encorafenib plus binimetinib in patients with <i>BRAF</i> <sup>V600</sup> -mutant non-small cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
619	BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 863043.	1.3	16
620	Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance. <i>Cancers</i> , 2022, 14, 1321.	1.7	29
621	Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance. <i>Cancers</i> , 2022, 14, 1783.	1.7	3
622	A Novel LOC101927967 Intergenic Region ALK Fusion Identified by NGS and Validated by IHC and FISH in a Patient with Early Stage Adenocarcinoma of Lung. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 251-254.	1.0	0

#	ARTICLE	IF	CITATIONS
623	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced <i>ALK</i> + Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. <i>Clinical Cancer Research</i> , 2022, 28, 1800-1808.	3.2	26
624	Custom multi-tumor next-generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three-year clinical use. <i>International Journal of Molecular Medicine</i> , 2022, 49, .	1.8	2
625	A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands. <i>European Journal of Cancer</i> , 2022, 165, 195-204.	1.3	5
626	Trends of Molecular Testing for Lung Cancer at the King Faisal Hospital, Kigali: Therapeutic and Survival Implications. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100304.	0.6	0
627	Novel targeted therapies for advanced non-small lung cancer. <i>Seminars in Oncology</i> , 2022, 49, 326-336.	0.8	9
628	Integrated Bioinformatics Analysis Identifies a New Stemness Index-Related Survival Model for Prognostic Prediction in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 860268.	1.1	7
629	Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort. <i>European Journal of Cancer</i> , 2022, 166, 51-59.	1.3	14
630	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Current Oncology</i> , 2021, 28, 5278-5294.	0.9	5
631	Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. <i>Cancers</i> , 2022, 14, 92.	1.7	3
632	Unlocking Access to Broad Molecular Profiling: Benefits, Barriers, and Policy Solutions. <i>Public Health Genomics</i> , 2022, 25, 70-79.	0.6	2
642	Clinicopathological aspects of V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small cell lung carcinoma in an Indian cohort: is there a difference?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2021, 12, 112-119.	0.4	0
643	Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. <i>Clinical Oncology</i> , 2022, , .	0.6	0
644	Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1071-1083.	0.5	2
645	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 499-514.	12.5	140
647	Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management. <i>Minerva Medica</i> , 2022, 113, 315-332.	0.3	3
648	B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors. <i>World Journal of Surgical Oncology</i> , 2022, 20, 159.	0.8	8
649	A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 1297.	1.3	2
650	Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2613.	1.7	8

#	ARTICLE	IF	CITATIONS
651	Concordance Between Tissue ALK Detection by Immunohistochemistry and Plasma ALK Detection by Next-Generation Sequencing in the Randomized Phase 3 ALEX Study in Patients with Treatment-Naïve Advanced ALK-Positive NSCLC. JTO Clinical and Research Reports, 2022, , 100341.	0.6	0
652	Management of Malignant Pleural Effusion: Where Are We Now?. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 559-569.	0.8	1
653	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. Lung Cancer, 2022, 169, 102-114.	0.9	8
654	The efficacy and safety of selumetinib as secondary therapy for late-stage and metastatic non-small cell lung cancer: results from a systematic review and meta-analysis. Annals of Translational Medicine, 2022, 10, 593-593.	0.7	1
655	Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1943-1953.	1.2	1
657	Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort. Journal of Thoracic Disease, 2021, .	0.6	2
658	Transfer Learning for the Classification of Small-Cell and Non-small-Cell Lung Cancer. Communications in Computer and Information Science, 2022, , 341-348.	0.4	2
659	Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100367.	0.6	13
661	Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation. Frontiers in Oncology, 0, 12, .	1.3	5
662	Targeting molecular alterations in non-small-cell lung cancer: what's next?. Personalized Medicine, 0, .	0.8	4
663	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer. European Journal of Cancer, 2022, 171, 114-123.	1.3	5
664	MOLECULAR PROFILE OF NON-SMALL CELL LUNG CANCER IN REUNION ISLAND. Respiratory Medicine and Research, 2022, , 100939.	0.4	0
665	Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Current Oncology, 2022, 29, 4811-4826.	0.9	8
666	Prospective role and immunotherapeutic targets of sideroflexin protein family in lung adenocarcinoma: evidence from bioinformatics validation. Functional and Integrative Genomics, 2022, 22, 1057-1072.	1.4	30
667	Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer. Diagnostics, 2022, 12, 1799.	1.3	7
668	Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials. JTO Clinical and Research Reports, 2022, 3, 100385.	0.6	3
669	Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Frontiers in Immunology, 0, 13, .	2.2	5
670	Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement. Lung Cancer, 2022, 172, 142-153.	0.9	3

#	ARTICLE	IF	CITATIONS
671	Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in nonâ€“small cell lung cancer: an observational, retrospective, pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 237-242.	1.0	3
672	State-of-the-art combination treatment strategies for advanced stage nonâ€“small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
673	Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. <i>Cancers</i> , 2022, 14, 4103.	1.7	14
674	Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors. <i>Toxicology and Applied Pharmacology</i> , 2022, 453, 116213.	1.3	2
675	Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). <i>Lung Cancer</i> , 2022, 173, 83-93.	0.9	5
676	The role of psychiatry in quality of life in young patients with non-small cell lung cancer. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2022, 25, 100507.	1.3	1
677	Genomic Alterations in Lung Cancer. <i>Medical Radiology</i> , 2022, , .	0.0	0
678	Brigatinib in Japanese patients with tyrosine kinase inhibitor-naïve ALK-positive non-small cell lung cancer: first results from the phase 2AJ-ALTA study. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1828-1838.	1.0	4
679	Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report. <i>Medicine (United States)</i> , 2022, 101, e30255.	0.4	0
680	Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study. <i>Clinical Lung Cancer</i> , 2023, 24, 1-10.	1.1	4
681	Protocol of an iterative qualitative study to develop a molecular testing decision aid for shared decision-making in patients with lung cancer after surgery. <i>BMJ Open</i> , 2022, 12, e061367.	0.8	2
682	ALKâ€“positive locally advanced lung cancer in a patient who achieved longâ€“term complete response with crizotinib: A case report. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	1
683	Cetuximab and Dabrafenib Plus Trametinib for Untreated Colonic Metastasis of BRAFV600E Mutant Primary Lung Adenocarcinoma with Signet Ring Cell Features: An Interesting and Rare Case Report. <i>OncoTargets and Therapy</i> , 0, Volume 15, 1057-1062.	1.0	0
684	Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study. <i>Targeted Oncology</i> , 2022, 17, 675-682.	1.7	9
685	The association between ROS1 rearrangement and risk of thromboembolic events in patients with advanced non-small cell lung cancer: a multicenter study in China. <i>Thrombosis Journal</i> , 2022, 20, .	0.9	4
686	An evaluation of sotorasib for the treatment of patients with nonâ€“small cell lung cancer with KRASG12C mutations. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1569-1575.	0.9	1
688	Management of Lung Cancer Presenting with Solitary Bone Metastasis. <i>Medicina (Lithuania)</i> , 2022, 58, 1463.	0.8	8
689	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59

#	ARTICLE	IF	CITATIONS
691	One-year mortality in lung cancer in France according to key time points of care pathways. ERJ Open Research, 0, , 00157-2022.	1.1	0
692	Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first-line therapy in adenocarcinoma patients. Cancer Medicine, 2023, 12, 5352-5363.	1.3	2
693	Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States. Clinical Lung Cancer, 2023, 24, e39-e49.	1.1	3
694	Identification of Novel MET Exon 14 Skipping Variants in Non-Small Cell Lung Cancer Patients: A Prototype Workflow Involving in Silico Prediction and RT-PCR. Cancers, 2022, 14, 4814.	1.7	3
696	Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. AboutOpen, 0, 9, 92-104.	0.2	0
698	Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	1
699	Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. Lung Cancer, 2022, 174, 45-49.	0.9	4
700	Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
701	Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection. Expert Review of Respiratory Medicine, 2022, 16, 1043-1055.	1.0	1
702	Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun. Current Treatment Options in Oncology, 2022, 23, 1699-1720.	1.3	5
703	Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer. Frontiers in Oncology, 0, 12, .	1.3	5
704	Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. ESMO Open, 2022, 7, 100612.	2.0	3
705	Evaluate the Prognosis of <i>MYC/TP53</i> Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study. Technology in Cancer Research and Treatment, 2022, 21, 153303382211382.	0.8	1
706	Update on new treatments for rare ovarian tumours. Current Opinion in Obstetrics and Gynecology, 2023, 35, 27-33.	0.9	2
707	The Impact of Targetable Mutations on Clinical Outcomes of Metastatic Epidural Spinal Cord Compression in Patients With Non-Small-Cell Lung Cancer Treated With Hybrid Therapy (Surgery) Tj ETQq0 0 0 r gBT /Overlock 10 Tf	0.8	1
708	Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. European Journal of Cancer, 2023, 181, 53-61.	1.3	5
709	An update on lorlatinib: a novel first line treatment for <i>ALK</i>-positive advanced lung cancer. Expert Opinion on Pharmacotherapy, 2023, 24, 291-299.	0.9	1
710	Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor. International Journal of Molecular Sciences, 2022, 23, 15828.	1.8	3

#	ARTICLE	IF	CITATIONS
711	Caracterizaci3n molecular por secuenciaci3n de nueva generaci3n obtenida en biopsia l3quida en una cohorte multic3ntrica de pacientes con diagn3stico de c3ncer de pulm3n avanzado en Argentina. , 2022, 27, .		0
713	Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. Lung Cancer, 2023, 176, 103-111.	0.9	8
715	Removing different number of regional lymph nodes affects survival outcomes of operable patients at stage IIA non-small cell lung cancer (according to the 8th edition staging). Journal of Thoracic Disease, 2023, .	0.6	0
716	Differential Gene Expression Analysis of Non-Small Cell Lung Cancer Samples to Classify Candidate Genes. Engineering, Technology & Applied Science Research, 2023, 13, 10571-10577.	0.8	1
717	Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan. Value in Health Regional Issues, 2023, 35, 48-56.	0.5	0
718	Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges. Cancer Treatment Reviews, 2023, 114, 102520.	3.4	8
719	First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN. JTO Clinical and Research Reports, 2023, 4, 100471.	0.6	0
720	Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience. International Journal of Gynecological Cancer, 2023, 33, 514-520.	1.2	0
721	Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 2023, 66, 2566-2588.	2.9	5
722	Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. Biomedicines, 2023, 11, 508.	1.4	3
723	The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study. Annals of Translational Medicine, 2023, 11, 157-157.	0.7	2
724	Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices. Current Oncology, 2023, 30, 2348-2365.	0.9	8
725	Real-World Comparative Effectiveness of First-Line Alectinib Versus Crizotinib in Patients With Advanced ALK-Positive NSCLC With or Without Baseline Central Nervous System Metastases. JTO Clinical and Research Reports, 2023, 4, 100483.	0.6	0
726	Current and future applications of liquid biopsy in non-small-cell lung cancerâ€”a narrative review. Translational Lung Cancer Research, 2023, 12, 594-614.	1.3	6
727	Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital. Cancers, 2023, 15, 1705.	1.7	4
728	Acquired L718V/TP53 co-mutation and discordant molecular pattern between plasmatic and cerebrospinal fluid in a bone and meningeal metastatic L858R+ non-small cell lung cancer: a case report. Annals of Translational Medicine, 2023, 11, 223-223.	0.7	0
729	Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting. Clinical Lung Cancer, 2023, 24, 429-436.	1.1	3
730	Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer. Cancers, 2023, 15, 1877.	1.7	4

#	ARTICLE	IF	CITATIONS
731	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
732	Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
734	Epigenetic therapy in lung cancer. , 2023, , 237-274.		0
754	EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)â€”A Podcast Discussion Between Patients and Oncologists. <i>Oncology and Therapy</i> , 0, , .	1.0	0
756	Histology and molecular testing. , 2024, , 69-100.		0
761	Hope and its associated factors in cancer patients undergoing drug therapy: a systematic review. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	0
777	Lung cancer in patients who have never smoked â€” an emerging disease. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 121-146.	12.5	1